Ferric Carboxymaltose Gets Boxed Warning for Low Phosphate

The warning changes the risk conversation

The FDA’s September 2026 action gives hypophosphatemia the most prominent warning in the prescribing information for ferric carboxymaltose. A boxed warning does not automatically make a drug inappropriate, but it raises the threshold for selecting it without first considering patient-specific susceptibility, alternative intravenous iron products and the feasibility of follow-up.

The concern is not limited to an asymptomatic laboratory abnormality. Clinically important hypophosphatemia can cause worsening fatigue, muscle weakness, myalgia and bone pain—symptoms that may be mistaken for persistent iron deficiency or the underlying illness. Prolonged or recurrent phosphate depletion can contribute to osteomalacia and fractures.

The revised warning should therefore be incorporated into shared decision-making before treatment. Patients need to understand why ferric carboxymaltose is being considered, whether reasonable alternatives exist and which new or persistent symptoms should prompt phosphate evaluation.

Comparative trials found a product-specific difference

Randomized evidence predating the boxed warning showed substantially more hypophosphatemia with ferric carboxymaltose than with two other intravenous iron formulations. These trials support a causal drug effect in the studied populations, although their incidence estimates should not be applied to every clinical setting.

Two open-label randomized trials published in JAMA included 245 adults with iron-deficiency anemia who were intolerant of, or had an inadequate response to, oral iron. Participants received either iron isomaltoside, now called ferric derisomaltose, or ferric carboxymaltose and were followed for 35 days. The primary outcome was serum phosphate below 2.0 mg/dL at any time from baseline through day 35.

In both JAMA trials, between-group differences were statistically significant, with P values below .001. The dosing schedules differed between products, as they do in usual administration, so the comparison reflects the tested treatment courses rather than equal milligram-for-milligram exposure.

A separate randomized, double-blind trial followed 1,997 adults with iron-deficiency anemia for five weeks after treatment with ferric carboxymaltose or ferumoxytol. Severe hypophosphatemia, defined as phosphate below 2.0 mg/dL, occurred in 50.8% of the ferric carboxymaltose group and 0.9% of the ferumoxytol group. Levels below 1.3 mg/dL occurred in 10.0% and 0%, respectively. At the end of follow-up, hypophosphatemia persisted in 29.1% of ferric carboxymaltose recipients and none of those receiving ferumoxytol.

Mechanistic measurements in that trial linked ferric carboxymaltose to increases in biologically active fibroblast growth factor 23. This promotes urinary phosphate loss and reduces active vitamin D, with downstream changes in calcium and parathyroid hormone regulation. The findings help explain why replacing iron does not itself correct the phosphate disturbance.

Applying the warning when choosing intravenous iron

Treatment selection should start with why intravenous iron is needed and the relative benefits and risks of available formulations. Ferric carboxymaltose may offer practical advantages in some settings, but convenience should now be weighed explicitly against its comparative phosphate risk. Other considerations include prior reactions, comorbidities, infusion capacity, expected need for repeated courses, insurance coverage and the evidence for each product in the relevant disease.

The warning is especially consequential when recurrent treatment is foreseeable. Repeated exposure can extend the period of renal phosphate wasting and may allow cumulative skeletal complications to develop before the association is recognized. A previous uncomplicated course does not establish that subsequent courses will be free of hypophosphatemia.

Risk assessment should include baseline phosphate status and factors that may reduce phosphate reserves or alter mineral metabolism. These include vitamin D deficiency, malnutrition, malabsorption, hyperparathyroidism and a history of low phosphate. Prior or planned repeated ferric carboxymaltose exposure also matters. Kidney function can modify risk: patients with preserved filtration may have a greater capacity for fibroblast growth factor 23-mediated urinary phosphate loss than those with advanced kidney disease, although chronic kidney disease introduces other mineral abnormalities that complicate interpretation.

The evidence supports considering an alternative intravenous iron formulation when clinically appropriate, particularly for a patient with pre-existing hypophosphatemia, strong risk factors or an expected need for repeated treatment. The boxed warning is not, by itself, evidence that every patient must avoid ferric carboxymaltose.

Counseling and phosphate evaluation

Before treatment, clinicians should follow the revised prescribing information to identify at-risk patients, correct pre-existing abnormalities, and determine when to measure serum phosphate. A recent phosphate level is particularly relevant when risk factors are present or another course is being contemplated. Evaluation may also require calcium, kidney function, vitamin D and parathyroid hormone measurements when the cause or persistence of hypophosphatemia is unclear.

Patients should be told that fatigue may not improve—or may recur—for reasons other than inadequate iron replacement. New weakness, muscle pain, bone pain, difficulty walking or fractures warrant assessment rather than automatic retreatment for presumed iron deficiency. Because symptoms are nonspecific, serum phosphate is necessary to establish the abnormality.

Trial data indicate that phosphate can fall after the infusion and remain low for weeks. Testing immediately after administration may therefore miss the nadir. The revised label should determine routine monitoring intervals, while symptoms should prompt testing regardless of the scheduled follow-up date. Before repeat exposure, clinicians should verify that clinically important hypophosphatemia has resolved and reassess whether the same formulation remains the best option.

Important limits in the evidence

The FDA action communicates regulatory concern but does not provide a single incidence estimate applicable to all patients. Trial rates depended on the phosphate threshold, dosing course, sampling schedule, comparator and enrolled population. The randomized studies were designed around laboratory outcomes over approximately five weeks; they were not powered to quantify uncommon fractures, osteomalacia or other long-term clinical outcomes.

People with complex kidney, gastrointestinal or endocrine disease may differ from trial participants. Comparative data also do not establish that every alternative intravenous iron product has equivalent efficacy, access or safety for every indication. Longer-term studies are needed to define which patients develop persistent disease, the optimal monitoring schedule and the best management strategy after a clinically important decline.

Questions clinicians ask

Does every patient need a phosphate level before treatment?

The evidence does not establish universal baseline testing for every recipient. The boxed warning makes assessment more important when phosphate is already low, risk factors for depletion are present, symptoms are difficult to distinguish from anemia or repeated ferric carboxymaltose courses are planned; clinicians should follow the revised label’s specific testing requirements.

When should phosphate be checked after an infusion?

Randomized trials found declines during the weeks after treatment, so an immediate post-infusion result may not capture the lowest value. Follow-up should follow the timing specified in the revised prescribing information, with earlier or additional testing for compatible symptoms and reassessment before repeat exposure in at-risk patients.

Should ferric carboxymaltose no longer be used?

No. A boxed warning highlights a serious risk rather than creating a universal contraindication. Selection should account for the indication, comparative phosphate risk, prior response, comorbidities, likelihood of repeated treatment and whether another intravenous iron formulation can provide suitable iron replacement.

What if fatigue persists after iron treatment?

Persistent fatigue should not automatically be attributed to unresolved iron deficiency. Because hypophosphatemia can produce fatigue, weakness and muscle symptoms, clinicians should consider serum phosphate alongside the hemoglobin and iron response, particularly after ferric carboxymaltose or when additional treatment is being considered.

References

1. FDA adds boxed warning for Injectafer hypophosphatemia — US Food and Drug Administration, 2026 2. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials — JAMA, 2020 3. Randomized Trial of Intravenous Iron-Induced Hypophosphatemia — JCI Insight, 2018